| abstract |
Disclosed are a biomarker combination for assessing the risk of adenoma and colorectal cancer, and the use thereof, in particular a metabolic marker for assessing the risk of adenoma and colorectal cancer of a subject, and the use thereof in the preparation of a diagnostic product for evaluating the risk of adenoma and colorectal cancer. The diagnostic marker has the characteristics of high sensitivity and specificity, has higher sensitivity and specificity for early colorectal cancer diagnosis, and can be used for the early discovery of colorectal cancer, so as to buy time for patients, allow treatment to be started as soon as possible, and improve the clinical treatment effect. |